{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:09:56Z","timestamp":1773274196180,"version":"3.50.1"},"reference-count":54,"publisher":"American Association for Cancer Research (AACR)","issue":"16","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Peroxisome proliferator-activated receptors (PPARs) are lipid-sensing nuclear receptors that have been implicated in multiple physiologic processes including cancer. Here, we determine that PPAR\u03b4 induces cell proliferation through a novel cyclin E1\u2013dependent mechanism and is up-regulated in many human thyroid tumors. The expression of PPAR\u03b4 was induced coordinately with proliferation in primary human thyroid cells by the activation of serum, thyroid-stimulating hormone\/cyclic AMP, or epidermal growth factor\/mitogen-activated protein kinase mitogenic signaling pathways. Engineered overexpression of PPAR\u03b4 increased thyroid cell number, the incorporation of bromodeoxyuridine, and the phosphorylation of retinoblastoma protein by 40% to 45% in just 2 days, one usual cell population doubling. The synthetic PPAR\u03b4 agonist GW501516 augmented these PPAR\u03b4 proliferation effects in a dose-dependent manner. Overexpression of PPAR\u03b4 increased cyclin E1 protein by 9-fold, whereas knockdown of PPAR\u03b4 by small inhibitory RNA reduced both cyclin E1 protein and cell proliferation by 2-fold. Induction of proliferation by PPAR\u03b4 was abrogated by knockdown of cyclin E1 by small inhibitory RNA in primary thyroid cells and by knockout of cyclin E1 in mouse embryo fibroblasts, confirming a cyclin E1 dependence for this PPAR\u03b4 pathway. In addition, the mean expression of native PPAR\u03b4 was increased by 2-fold to 5-fold (P &amp;lt; 0.0001) and correlated with that of the in situ proliferation marker Ki67 (R = 0.8571; P = 0.02381) in six different classes of benign and malignant human thyroid tumors. Our experiments identify a PPAR\u03b4 mechanism that induces cell proliferation through cyclin E1 and is regulated by growth factor and lipid signals. The data argue for systematic investigation of PPAR\u03b4 antagonists as antineoplastic agents and implicate altered PPAR\u03b4\u2013cyclin E1 signaling in thyroid and other carcinomas. [Cancer Res 2008;68(16):6578\u201386]<\/jats:p>","DOI":"10.1158\/0008-5472.can-08-0855","type":"journal-article","created":{"date-parts":[[2008,8,13]],"date-time":"2008-08-13T00:48:12Z","timestamp":1218588492000},"page":"6578-6586","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Peroxisome Proliferator-Activated Receptor-\u03b4 Induces Cell Proliferation by a Cyclin E1\u2013Dependent Mechanism and Is Up-regulated in Thyroid Tumors"],"prefix":"10.1158","volume":"68","author":[{"given":"Lingchun","family":"Zeng","sequence":"first","affiliation":[{"name":"1Department of Pathology, University of Chicago School of Medicine, University of Chicago Cancer Research Center, Chicago, Illinois and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Geng","sequence":"additional","affiliation":[{"name":"2Department of Cancer Biology, Dana-Farber Cancer Institute and Department of Pathology, Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Tretiakova","sequence":"additional","affiliation":[{"name":"1Department of Pathology, University of Chicago School of Medicine, University of Chicago Cancer Research Center, Chicago, Illinois and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuemei","family":"Yu","sequence":"additional","affiliation":[{"name":"1Department of Pathology, University of Chicago School of Medicine, University of Chicago Cancer Research Center, Chicago, Illinois and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Sicinski","sequence":"additional","affiliation":[{"name":"2Department of Cancer Biology, Dana-Farber Cancer Institute and Department of Pathology, Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd G.","family":"Kroll","sequence":"additional","affiliation":[{"name":"1Department of Pathology, University of Chicago School of Medicine, University of Chicago Cancer Research Center, Chicago, Illinois and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2008,8,12]]},"reference":[{"key":"2022061623235137200_B1","doi-asserted-by":"crossref","unstructured":"Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med\u20082004; 10: 355\u201361.","DOI":"10.1038\/nm1025"},{"key":"2022061623235137200_B2","doi-asserted-by":"crossref","unstructured":"Rosen ED, Spiegelman BM. PPAR\u03b3: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem\u20082001; 276: 37731\u20134.","DOI":"10.1074\/jbc.R100034200"},{"key":"2022061623235137200_B3","doi-asserted-by":"crossref","unstructured":"Bookout AL, Jeong Y, Downes M, et al. Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell\u20082006; 126: 789\u201399.","DOI":"10.1016\/j.cell.2006.06.049"},{"key":"2022061623235137200_B4","doi-asserted-by":"crossref","unstructured":"Issemann I, Prince RA, Tugwood JD, et al. The peroxisome proliferator-activated receptor:retinoid X receptor heterodimer is activated by fatty acids and fibrate hypolipidaemic drugs. J Mol Endocrinol\u20081993; 11: 37\u201347.","DOI":"10.1677\/jme.0.0110037"},{"key":"2022061623235137200_B5","doi-asserted-by":"crossref","unstructured":"Barish GD, Evans RM. PPARs and LXRs: Atherosclerosis goes nuclear. Trends Endocrinol Metab\u20082004; 15: 158\u201365.","DOI":"10.1016\/j.tem.2004.03.003"},{"key":"2022061623235137200_B6","doi-asserted-by":"crossref","unstructured":"Rosen ED, Spiegelman BM. Molecular regulation of adipogenesis. Annu Rev Cell Dev Biol\u20082000; 16: 145\u201371.","DOI":"10.1146\/annurev.cellbio.16.1.145"},{"key":"2022061623235137200_B7","doi-asserted-by":"crossref","unstructured":"Lehmann JM, Moore LB, Smith-Oliver TA, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3). J Biol Chem\u20081995; 270: 12953\u20136.","DOI":"10.1074\/jbc.270.22.12953"},{"key":"2022061623235137200_B8","doi-asserted-by":"crossref","unstructured":"Tanaka T, Yamamoto J, Iwasaki S, et al. Activation of peroxisome proliferator-activated receptor \u03b4 induces fatty acid \u03b2-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci U S A\u20082003; 100: 15924\u20139.","DOI":"10.1073\/pnas.0306981100"},{"key":"2022061623235137200_B9","doi-asserted-by":"crossref","unstructured":"Schuler M, Ali F, Chambon C, et al. PGC1\u03b1 expression is controlled in skeletal muscles by PPAR\u03b2, whose ablation results in fiber-type switching, obesity, and type 2 diabetes. Cell Metab\u20082006; 4: 407\u201314.","DOI":"10.1016\/j.cmet.2006.10.003"},{"key":"2022061623235137200_B10","doi-asserted-by":"crossref","unstructured":"Peters JM, Lee SS, Li W, et al. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor \u03b2(\u03b4). Mol Cell Biol\u20082000; 20: 5119\u201328.","DOI":"10.1128\/MCB.20.14.5119-5128.2000"},{"key":"2022061623235137200_B11","doi-asserted-by":"crossref","unstructured":"Oliver WR, Jr., Shenk JL, Snaith MR, et al. A selective peroxisome proliferator-activated receptor \u03b4 agonist promotes reverse cholesterol transport. Proc Natl Acad Sci U S A\u20082001; 98: 5306\u201311.","DOI":"10.1073\/pnas.091021198"},{"key":"2022061623235137200_B12","doi-asserted-by":"crossref","unstructured":"Sprecher DL, Massien C, Pearce G, et al. Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor \u03b4 agonist. Arterioscler Thromb Vasc Biol\u20082007; 27: 359\u201365.","DOI":"10.1161\/01.ATV.0000252790.70572.0c"},{"key":"2022061623235137200_B13","doi-asserted-by":"crossref","unstructured":"Lee SS, Pineau T, Drago J, et al. Targeted disruption of the \u03b1 isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol\u20081995; 15: 3012\u201322.","DOI":"10.1128\/MCB.15.6.3012"},{"key":"2022061623235137200_B14","doi-asserted-by":"crossref","unstructured":"Park BH, Vogelstein B, Kinzler KW. Genetic disruption of PPAR\u03b4 decreases the tumorigenicity of human colon cancer cells. Proc Natl Acad Sci U S A\u20082001; 98: 2598\u2013603.","DOI":"10.1073\/pnas.051630998"},{"key":"2022061623235137200_B15","doi-asserted-by":"crossref","unstructured":"Harman FS, Nicol CJ, Marin HE, et al. Peroxisome proliferator-activated receptor-\u03b4 attenuates colon carcinogenesis. Nat Med\u20082004; 10: 481\u20133.","DOI":"10.1038\/nm1026"},{"key":"2022061623235137200_B16","doi-asserted-by":"crossref","unstructured":"Girnun GD, Smith WM, Drori S, et al. APC-dependent suppression of colon carcinogenesis by ppar\u03b3. Proc Natl Acad Sci U S A\u20082002; 99: 13771\u20136.","DOI":"10.1073\/pnas.162480299"},{"key":"2022061623235137200_B17","doi-asserted-by":"crossref","unstructured":"Saez E, Tontonoz P, Nelson MC, et al. Activators of the nuclear receptor PPAR\u03b3 enhance colon polyp formation. Nat Med\u20081998; 4: 1058\u201361.","DOI":"10.1038\/2042"},{"key":"2022061623235137200_B18","doi-asserted-by":"crossref","unstructured":"Gupta RA, Wang D, Katkuri S, et al. Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-\u03b4 accelerates intestinal adenoma growth. Nat Med\u20082004; 10: 245\u20137.","DOI":"10.1038\/nm993"},{"key":"2022061623235137200_B19","doi-asserted-by":"crossref","unstructured":"Sarraf P, Mueller E, Smith WM, et al. Loss-of-function mutations in PPAR \u03b3 associated with human colon cancer. Mol Cell\u20081999; 3: 799\u2013804.","DOI":"10.1016\/S1097-2765(01)80012-5"},{"key":"2022061623235137200_B20","doi-asserted-by":"crossref","unstructured":"French CA, Alexander EK, Cibas ES, et al. Genetic and biological subgroups of low-stage follicular thyroid cancer. Am J Pathol\u20082003; 162: 1053\u201360.","DOI":"10.1016\/S0002-9440(10)63902-8"},{"key":"2022061623235137200_B21","doi-asserted-by":"crossref","unstructured":"Kroll TG, Sarraf P, Pecciarini L, et al. PAX8-1 fusion oncogene in human thyroid carcinoma [corrected]. Science\u20082000; 289: 1357\u201360.","DOI":"10.1126\/science.289.5483.1357"},{"key":"2022061623235137200_B22","doi-asserted-by":"crossref","unstructured":"Williams DW, Wynford-Thomas D. Human thyroid epithelial cells. Methods Mol Biol\u20081997; 75: 163\u201372.","DOI":"10.1385\/0-89603-441-0:163"},{"key":"2022061623235137200_B23","unstructured":"Reiner A, Neumeister B, Spona J, et al. Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer. Cancer Res\u20081990; 50: 7057\u201361."},{"key":"2022061623235137200_B24","doi-asserted-by":"crossref","unstructured":"Kimura T, Van Keymeulen A, Golstein J, et al. Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models. Endocr Rev\u20082001; 22: 631\u201356.","DOI":"10.1210\/edrv.22.5.0444"},{"key":"2022061623235137200_B25","doi-asserted-by":"crossref","unstructured":"Geng Y, Yu Q, Sicinska E, et al. Cyclin E ablation in the mouse. Cell\u20082003; 114: 431\u201343.","DOI":"10.1016\/S0092-8674(03)00645-7"},{"key":"2022061623235137200_B26","doi-asserted-by":"crossref","unstructured":"Barak Y, Liao D, He W, et al. Effects of peroxisome proliferator-activated receptor \u03b4 on placentation, adiposity, and colorectal cancer. Proc Natl Acad Sci U S A\u20082002; 99: 303\u20138.","DOI":"10.1073\/pnas.012610299"},{"key":"2022061623235137200_B27","doi-asserted-by":"crossref","unstructured":"Zhang J, Fu M, Zhu X, et al. Peroxisome proliferator-activated receptor \u03b4 is up-regulated during vascular lesion formation and promotes post-confluent cell proliferation in vascular smooth muscle cells. J Biol Chem\u20082002; 277: 11505\u201312.","DOI":"10.1074\/jbc.M110580200"},{"key":"2022061623235137200_B28","doi-asserted-by":"crossref","unstructured":"Wang D, Wang H, Guo Y, et al. Crosstalk between peroxisome proliferator-activated receptor \u03b4 and VEGF stimulates cancer progression. Proc Natl Acad Sci U S A\u20082006; 103: 19069\u201374.","DOI":"10.1073\/pnas.0607948103"},{"key":"2022061623235137200_B29","doi-asserted-by":"crossref","unstructured":"Xu L, Han C, Wu T. A novel positive feedback loop between peroxisome proliferator-activated receptor-\u03b4 and prostaglandin E2 signaling pathways for human cholangiocarcinoma cell growth. J Biol Chem\u20082006; 281: 33982\u201396.","DOI":"10.1074\/jbc.M600135200"},{"key":"2022061623235137200_B30","doi-asserted-by":"crossref","unstructured":"Jehl-Pietri C, Bastie C, Gillot I, et al. Peroxisome-proliferator-activated receptor \u03b4 mediates the effects of long-chain fatty acids on post-confluent cell proliferation. Biochem J\u20082000; 350 Pt 1: 93\u20138.","DOI":"10.1042\/bj3500093"},{"key":"2022061623235137200_B31","doi-asserted-by":"crossref","unstructured":"Hansen JB, Zhang H, Rasmussen TH, et al. Peroxisome proliferator-activated receptor \u03b4 (PPAR\u03b4)-mediated regulation of preadipocyte proliferation and gene expression is dependent on cAMP signaling. J Biol Chem\u20082001; 276: 3175\u201382.","DOI":"10.1074\/jbc.M005567200"},{"key":"2022061623235137200_B32","doi-asserted-by":"crossref","unstructured":"Burdick AD, Bility MT, Girroir EE, et al. Ligand activation of peroxisome proliferator-activated receptor-\u03b2\/\u03b4(PPAR\u03b2\/\u03b4) inhibits cell growth of human n\/tert-1 keratinocytes. Cell Signal\u20082007; 19: 1163\u201371.","DOI":"10.1016\/j.cellsig.2006.12.007"},{"key":"2022061623235137200_B33","doi-asserted-by":"crossref","unstructured":"Kim DJ, Bility MT, Billin AN, et al. Ppar\u03b2\/\u03b4 selectively induces differentiation and inhibits cell proliferation. Cell Death Differ\u20082006; 13: 53\u201360.","DOI":"10.1038\/sj.cdd.4401713"},{"key":"2022061623235137200_B34","doi-asserted-by":"crossref","unstructured":"Sabatino L, Casamassimi A, Peluso G, et al. A novel peroxisome proliferator-activated receptor \u03b3 isoform with dominant negative activity generated by alternative splicing. J Biol Chem\u20082005; 280: 26517\u201325.","DOI":"10.1074\/jbc.M502716200"},{"key":"2022061623235137200_B35","doi-asserted-by":"crossref","unstructured":"Shi Y, Hon M, Evans RM. The peroxisome proliferator-activated receptor \u03b4, an integrator of transcriptional repression and nuclear receptor signaling. Proc Natl Acad Sci U S A\u20082002; 99: 2613\u20138.","DOI":"10.1073\/pnas.052707099"},{"key":"2022061623235137200_B36","unstructured":"Palakurthi SS, Aktas H, Grubissich LM, et al. Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor \u03b3 and mediated by inhibition of translation initiation. Cancer Res\u20082001; 61: 6213\u20138."},{"key":"2022061623235137200_B37","doi-asserted-by":"crossref","unstructured":"Baek SJ, Wilson LC, Hsi LC, et al. Troglitazone, a peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3) ligand, selectively induces the early growth response-1 gene independently of PPAR\u03b3. A novel mechanism for its anti-tumorigenic activity. J Biol Chem\u20082003; 278: 5845\u201353.","DOI":"10.1074\/jbc.M208394200"},{"key":"2022061623235137200_B38","doi-asserted-by":"crossref","unstructured":"Lazzereschi D, Sambuco L, Carnovale Scalzo C, et al. Cyclin D1 and cyclin E expression in malignant thyroid cells and in human thyroid carcinomas. Int J Cancer\u20081998; 76: 806\u201311.","DOI":"10.1002\/(SICI)1097-0215(19980610)76:6<806::AID-IJC7>3.0.CO;2-1"},{"key":"2022061623235137200_B39","doi-asserted-by":"crossref","unstructured":"Pickett CA, Agoff SN, Widman TJ, et al. Altered expression of cyclins and cell cycle inhibitors in papillary thyroid cancer: prognostic implications. Thyroid\u20082005; 15: 461\u201373.","DOI":"10.1089\/thy.2005.15.461"},{"key":"2022061623235137200_B40","doi-asserted-by":"crossref","unstructured":"Brzezinski J, Migodzinski A, Toczek A, et al. Patterns of cyclin E, retinoblastoma protein, and p21cip1\/waf1 immunostaining in the oncogenesis of papillary thyroid carcinoma. Clin Cancer Res\u20082005; 11: 1037\u201343.","DOI":"10.1158\/1078-0432.1037.11.3"},{"key":"2022061623235137200_B41","doi-asserted-by":"crossref","unstructured":"Brzezinski J, Migodzinski A, Gosek A, et al. Cyclin E expression in papillary thyroid carcinoma: relation to staging. Int J Cancer\u20082004; 109: 102\u20135.","DOI":"10.1002\/ijc.11673"},{"key":"2022061623235137200_B42","doi-asserted-by":"crossref","unstructured":"Melck A, Masoudi H, Griffith OL, et al. Cell cycle regulators show diagnostic and prognostic utility for differentiated thyroid cancer. Ann Surg Oncol\u20082007; 14: 3403\u201311.","DOI":"10.1245\/s10434-007-9572-8"},{"key":"2022061623235137200_B43","doi-asserted-by":"crossref","unstructured":"Wiseman SM, Masoudi H, Niblock P, et al. Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. Ann Surg Oncol\u20082007; 14: 719\u201329.","DOI":"10.1245\/s10434-006-9178-6"},{"key":"2022061623235137200_B44","doi-asserted-by":"crossref","unstructured":"Duronio RJ, O'Farrell PH. Developmental control of the G1 to S transition in drosophila: cyclin E is a limiting downstream target of E2f. Genes Dev\u20081995; 9: 1456\u201368.","DOI":"10.1101\/gad.9.12.1456"},{"key":"2022061623235137200_B45","doi-asserted-by":"crossref","unstructured":"Spruck CH, Won KA, Reed SI. Deregulated cyclin E induces chromosome instability. Nature\u20081999; 401: 297\u2013300.","DOI":"10.1038\/45836"},{"key":"2022061623235137200_B46","doi-asserted-by":"crossref","unstructured":"Keyomarsi K, Tucker SL, Buchholz TA, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med\u20082002; 347: 1566\u201375.","DOI":"10.1056\/NEJMoa021153"},{"key":"2022061623235137200_B47","doi-asserted-by":"crossref","unstructured":"Yin Y, Russell RG, Dettin LE, et al. Peroxisome proliferator-activated receptor \u03b4 and \u03b3 agonists differentially alter tumor differentiation and progression during mammary carcinogenesis. Cancer Res\u20082005; 65: 3950\u20137.","DOI":"10.1158\/0008-5472.CAN-04-3990"},{"key":"2022061623235137200_B48","doi-asserted-by":"crossref","unstructured":"Powell J, Wang X, Allard B, et al. The PAX8\/PPAR\u03b3 fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPAR\u03b3 inhibition. Oncogene\u20082004; 23: 3634\u201341.","DOI":"10.1038\/sj.onc.1207399"},{"key":"2022061623235137200_B49","doi-asserted-by":"crossref","unstructured":"Zhu Z, Gandhi M, Nikiforova MN, et al. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of RAS mutations. Am J Clin Pathol\u20082003; 120: 71\u20137.","DOI":"10.1309\/ND8D9LAJTRCTG6QD"},{"key":"2022061623235137200_B50","doi-asserted-by":"crossref","unstructured":"Santoro M, Carlomagno F, Hay ID, et al. Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J Clin Invest\u20081992; 89: 1517\u201322.","DOI":"10.1172\/JCI115743"},{"key":"2022061623235137200_B51","unstructured":"Kimura ET, Nikiforova MN, Zhu Z, et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of theret\/ptc-ras-braf signaling pathway in papillary thyroid carcinoma. Cancer Res\u20082003; 63: 1454\u20137."},{"key":"2022061623235137200_B52","unstructured":"Bongarzone I, Pierotti MA, Monzini N, et al. High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma. Oncogene\u20081989; 4: 1457\u201362."},{"key":"2022061623235137200_B53","unstructured":"Shao J, Sheng H, DuBois RN. Peroxisome proliferator-activated receptors modulate k-ras-mediated transformation of intestinal epithelial cells. Cancer Res\u20082002; 62: 3282\u20138."},{"key":"2022061623235137200_B54","doi-asserted-by":"crossref","unstructured":"Shearer BG, Steger DJ, Way JM, et al. Identification and characterization of a selective peroxisome proliferator-activated receptor {\u03b2}\/{\u03b4} (NR1C2) antagonist. Mol Endocrinol\u20082008; 22: 523\u20139.","DOI":"10.1210\/me.2007-0190"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/16\/6578\/2592207\/6578.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/16\/6578\/2592207\/6578.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T11:16:31Z","timestamp":1684494991000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/68\/16\/6578\/540677\/Peroxisome-Proliferator-Activated-Receptor-Induces"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,12]]},"references-count":54,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2008,8,12]]},"published-print":{"date-parts":[[2008,8,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-08-0855","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.22375500","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22375497","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6497850","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6497850.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22375497.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22375500.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,12]]}}}